| clinical trial | Q30612 |
| P3098 | ClinicalTrials.gov ID | NCT01826487 |
| P6099 | clinical trial phase | phase III clinical trial | Q42824827 |
| P17 | country | Canada | Q16 |
| Spain | Q29 | ||
| United States of America | Q30 | ||
| Belgium | Q31 | ||
| Sweden | Q34 | ||
| Poland | Q36 | ||
| Italy | Q38 | ||
| Switzerland | Q39 | ||
| Turkey | Q43 | ||
| France | Q142 | ||
| United Kingdom | Q145 | ||
| Brazil | Q155 | ||
| Germany | Q183 | ||
| Chile | Q298 | ||
| Israel | Q801 | ||
| Australia | Q408 | ||
| P582 | end time | 2015-08-01 | |
| P921 | main subject | ataluren | Q753330 |
| Becker muscular dystrophy | Q2484592 | ||
| P4135 | maximum age | 16 | |
| P2899 | minimum age | 7 | |
| P1132 | number of participants | 230 | |
| P6153 | research site | Harvard University | Q13371 |
| Columbia University | Q49088 | ||
| University of California, Los Angeles | Q174710 | ||
| University of Minnesota | Q238101 | ||
| Oregon Health & Science University | Q282097 | ||
| Medical University of Warsaw | Q496351 | ||
| Katholieke Universiteit Leuven | Q833670 | ||
| Rush University Medical Center | Q1535116 | ||
| Alberta Children's Hospital | Q2831698 | ||
| Children's Hospital of Eastern Ontario | Q2945735 | ||
| Seoul National University Hospital | Q4403855 | ||
| UPMC Children's Hospital of Pittsburgh | Q5098130 | ||
| Cincinnati Children's Hospital Medical Center | Q5120231 | ||
| Royal Manchester Children's Hospital | Q7374441 | ||
| University Hospital Brno | Q11989315 | ||
| Hadassah University Hospital, Mt. Scopus | Q16129695 | ||
| University of Iowa Health Care | Q30254145 | ||
| University of Kansas Medical Center | Q33526980 | ||
| University of Utah Health Care | Q56582915 | ||
| Hospital Sant Joan de Déu | Q64442914 | ||
| P1813 | short name | ACT DMD | |
| P580 | start time | 2013-03-01 | |
| P8363 | study type | interventional study | Q78089383 |
| P1476 | title | A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy |